Scientists redesign mRNA vaccine particles for stronger immunity with fewer side effects

Scientists at the University of Pennsylvania have made a breakthrough in vaccine technology by redesigning lipid nanoparticles (LNPs) used in mRNA vaccines. Their findings, published in Nature Materials on March 17, 2026, show how chemical tweaks to these particles can boost immune responses while reducing side effects. The discovery could lead to vaccines that work better, require smaller doses, and cause fewer reactions in patients.

The team focused on a new lipid variant called C12-2aN, which alters how immune cells process energy. Early results suggest this approach may improve not just infectious disease vaccines but also treatments for cancer and autoimmune conditions.

The researchers developed C12-2aN to target a key challenge in vaccine delivery: balancing strong immune activation with minimal inflammation. Traditional LNPs can trigger excessive systemic reactions, often leading to fever and discomfort. The new lipid design, however, steers more mRNA directly to lymphoid organs like lymph nodes, where immune responses are coordinated. This precision reduces wasted doses and enhances the vaccine's overall effectiveness.

Tests in animal models confirmed that C12-2aN nanoparticles matched the performance of FDA-approved mRNA formulations. But unlike standard versions, they also lowered body temperature spikes—a common marker of inflammation. The lipid's unique structure ramps up glycolytic activity in dendritic cells, the immune system's first responders. By fuelling these cells more efficiently, the vaccine prompts a stronger, longer-lasting defence without the usual trade-off of heightened side effects.

Beyond infectious diseases, the modified LNPs show potential in cancer immunotherapy and autoimmune therapies. Their ability to reprogram metabolic pathways in various immune cells opens doors for broader medical applications. Since the 2023 Nature Materials study, C12-2aN-based flu vaccines have entered Phase II clinical trials. A 2025 partnership with Pfizer is now advancing development, with Phase I/II data (NCT05839662) indicating improved stability and a favourable safety profile—no severe adverse effects reported so far.

The University of Pennsylvania's modified lipid nanoparticles represent a dual advance: sharper immune targeting and fewer inflammatory reactions. With Phase II trials underway for influenza and Pfizer's involvement in scaling the technology, the approach could soon redefine vaccine design. If successful, these next-generation mRNA vaccines may offer higher potency, lower doses, and greater public acceptance by minimising side effects.